ロード中...
BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancer
The androgen receptor (AR) is central to the initiation and progression of prostate cancer, even after castration. There has been some success in therapies targeting AR signaling which have been shown to extend survival in men with castration-resistant prostate cancer (CRPC). However, durable respon...
保存先:
| 出版年: | Cancer Biol Ther |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622075/ https://ncbi.nlm.nih.gov/pubmed/25535892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.962297 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|